Jiaqi Li

发表

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Depei Wu, Xiaowen Tang, Jin Zhou, 2021, Frontiers in Oncology.

A Nomogram to Predict Lymph Node Positivity Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Andrew D. Newton, A. Epstein, N. Mahmoud, 2016, Diseases of the colon and rectum.

Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study

A. Addeo, G. Banna, I. Oh, 2022, Translational lung cancer research.

Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy

T. Chu, Jiaqi Li, Yinchen Shen, 2022, Frontiers in Oncology.

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis

T. Chu, Jiaqi Li, Yinchen Shen, 2022, Frontiers in Oncology.

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis

Xiangshan Chen, Xi Chen, Yao Wang, 2023, Frontiers in Oncology.

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma

Depei Wu, Meng-jun Shan, Yang Xu, 2022, Frontiers in Immunology.

Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China

Juan Zhou, C. Su, T. Chu, 2022, International journal of cancer.

Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy

Juan Zhou, C. Su, F. Zhou, 2021, Translational lung cancer research.

Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Depei Wu, Jin Zhou, Ying Zhang, 2021, Blood.

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy

Xueyan Zhang, H. Zhong, Jun Lu, 2023, Clinical and translational medicine.

EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.

Jiaqi Li, C. Xiang, R. Zhao, 2024, Targeted oncology.